Brought to you by:
Clinical performance of Human Acellular Vessel amid war in Ukraine presented at military research symposium
Clinical outcomes of Humacyte’s investigational Human Acellular Vessel (HAV) were presented at the Military Health System Research Symposium in Kissimmee, Florida (Aug. 14–17), following a year-long humanitarian program in Ukraine. The bioengineered, implantable human tissue-based device was provided to five…
Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel for vascular trauma repair
Humacyte today announced completion of enrollment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA) filing for the company’s Human Acellular Vessel (HAV) in vascular trauma repair. A press release details…
VAM 2023: Vascular trauma session to highlight the current role of endovascular therapy
A focused session on vascular trauma yesterday took a deep dive into emerging issues and controversies in the field. Moderated by Sherene Shalhub, MD, of Oregon Health & Science University, Portland, Oregon, and Rishi Kundi, MD, of the R Adams…
Sudanese vascular association readies for first-ever conference
The Sudanese Association of Vascular Surgeons (SudAVaS) has announced the scientific program behind its first-ever international conference, marking the occasion by celebrating the “first steps in establishing vascular surgery as a standalone surgical specialty” in the northeast African country. The…
Human-tissue engineered blood vessels remain durable at six years in PAD patients, latest study results show
Mid-term results from a phase II study of surgical bypass using the Human Acellular Vessel (HAV) demonstrated an overall secondary patency rate at 72 months of 60% measured by Kaplan Meier. There was no evidence of graft rejection or infection,…
Veterans Day: Remembering Korea, ‘accidental pioneers’ and M*A*S*H
During November—Nov. 11, specifically—the United States salutes and honors all those who have served this country in its armed forces. This November, the Society for Vascular Surgery (SVS) highlights the Korean War, where vascular surgeons typically served in Mobile Army…
An open letter to the National Rifle Association
Hello, I think it is time we talked about guns. I know you don’t like to discuss these things after a school shooting, so I waited. It has been four months since Uvalde. It seems there have been three more…
A recent snapshot of pediatric vascular trauma injuries
A study of major pediatric vascular injuries delivered in the Vascular and Endovascular Surgery Society (VESS) Paper Session during the 2022 Vascular Annual Meeting (VAM) in June found that 70.2% of the cohort analyzed presented with penetrating trauma. More specifically,…
The top 10 most popular Vascular Specialist stories of August 2022
The top 10 most-read stories on the Vascular Specialist website in August included a look at the state of diversity, equity and inclusion (DEI) in vascular surgery, the confessions of dual-trained vascular- and trauma-trained surgeon, and the digital edition of…
Confessions of a dual-trained, dual-practicing vascular-trauma surgeon
Like most of the other readers of Vascular Specialist, I look forward to perusing each release for not just useful information but also insightful editorials that frame ongoing issues in thoughtful and entertaining ways. I personally find that I am…